Ghrelin is the body's primary hunger hormone — produced mainly in the stomach, it rises sharply before meals and falls after eating to signal fullness. This rise-and-fall cycle is essential for normal appetite regulation. The rs696217 variant (Leu72Met) substitutes leucine for methionine at position 72 of the preproghrelin protein — a region located between the mature ghrelin peptide and the obestatin segment¹¹ between the mature ghrelin peptide and the obestatin segment
The GHRL gene encodes a 117-amino-acid precursor; mature ghrelin is only 28 amino acids; position 72 sits in the C-terminal tail, outside mature ghrelin but within a region that influences processing and secretion. While the variant doesn't alter the mature ghrelin sequence itself, it appears to disrupt prohormone processing and mRNA stability²² disrupt prohormone processing and mRNA stability
The substitution may change how efficiently preproghrelin is cleaved, altering total ghrelin output and postprandial suppression kinetics, producing measurable downstream effects on appetite, lipid profiles, and metabolic disease risk.

The Mechanism

After a meal, postprandial ghrelin suppression³³ postprandial ghrelin suppression
Normally, eating causes ghrelin levels to drop by 30–50% within 60 minutes, signaling fullness to the hypothalamus is the key satiety signal from the gut. In carriers of the Met72 (T) allele, this suppression is blunted: ghrelin levels at 120 minutes postprandially remain significantly elevated compared to Leu72 homozygotes. The hypothalamus interprets persistently elevated ghrelin as continued hunger, driving greater food intake — particularly of high-sugar and high-starch foods. The variant may also affect obestatin co-processing⁴⁴ obestatin co-processing
Obestatin, a satiety peptide encoded in the same preproghrelin region, may be altered when the flanking amino acid at position 72 changes, further shifting the appetite balance toward hunger. Downstream effects include lower HDL-C, altered insulin sensitivity, and elevated adipokine profiles (decreased adiponectin, increased resistin) — together constituting the metabolic syndrome phenotype.

The Evidence

The landmark population study came from the Old Order Amish, where Korbonits et al. examined 856 adults⁵⁵ Korbonits et al. examined 856 adults
Amish Family Diabetes Study; comprehensive phenotyping including fasting glucose, lipids, insulin, waist circumference and found that Leu72Met carriers had a 2.57-fold higher odds of metabolic syndrome, with concurrently higher fasting glucose, lower HDL-C, and elevated triglycerides.

A 2018 meta-analysis of 13 case-control studies⁶⁶ 2018 meta-analysis of 13 case-control studies
Total 8,926 participants; 4,720 T2DM cases and 4,206 controls; studies from Europe, Asia, and the Arab world revealed a striking ethnic split: the T allele increases type 2 diabetes risk in Asians (OR 1.34, p = 0.040) but appears protective in Caucasians (OR 0.79, p = 0.030). The mechanism of this discordance is not fully understood but may reflect differences in linkage disequilibrium, epistatic background, or dietary environments across populations.

In a Turkish-Cypriot cohort of 211 adults⁷⁷ Turkish-Cypriot cohort of 211 adults
106 obese vs. 95 non-obese, rigorously phenotyped, the T allele appeared at 38% frequency in obese subjects vs. 22% in controls, with GT heterozygotes showing significantly lower HDL-C. A 2021 case-control study (310 participants)⁸⁸ 2021 case-control study (310 participants)
Biopsy-proven NAFLD diagnosis in 153 cases vs. 157 controls found the opposite pattern for fatty liver: GT/TT genotypes were substantially less common among NAFLD patients (OR 0.35), suggesting the Met72 allele may protect against fat accumulation in the liver while increasing it elsewhere.

The most clinically striking finding comes from a bariatric surgery cohort⁹⁹ bariatric surgery cohort
100 severely obese patients undergoing Roux-en-Y gastric bypass: GT heterozygotes lost 38.1% of BMI at 52 weeks vs. 30.5% in GG homozygotes (p < 0.001), suggesting the Met72 allele actually facilitates greater ghrelin reduction post-surgery and better weight loss outcomes.

A dietary intake study in 132 young adults¹⁰¹⁰ in 132 young adults
77% female, age 22 years, standardized meal challenge confirmed that Met allele carriers consumed significantly more fruit servings and added-sugar-containing bread and starch, consistent with impaired postprandial satiety driving sugar-seeking behavior.

Practical Implications

For GG homozygotes (the large majority), ghrelin dynamics are standard. For T allele carriers, the impaired postprandial suppression creates a biological drive toward higher food intake — particularly sugary and starchy foods — that is real, not a matter of willpower. High-protein meals suppress ghrelin more effectively than carbohydrate-rich meals and can compensate for the blunted suppression signal. Spacing meals with adequate protein and fiber, and avoiding rapid glycemic spikes that cause early return of hunger, are particularly important strategies for this genotype. Monitoring fasting glucose, HDL-C, and triglycerides annually is warranted given the metabolic syndrome associations, especially in populations where the T allele confers risk rather than protection.

Interactions

rs696217 interacts with the ghrelin promoter variant rs27647¹¹¹¹ rs27647
A-604G promoter SNP; affects GHRL transcription levels; may modulate total ghrelin output independently of processing changes at position 72. Carriers of T allele at rs696217 who also carry the risk allele at rs27647 may face compounded disruption of ghrelin regulation — affecting both total ghrelin levels (rs27647) and postprandial suppression (rs696217). The leptin system also interacts: ghrelin and leptin act in opposition on hypothalamic appetite circuits, and LEPR variants such as Gln223Arg¹²¹² LEPR variants such as Gln223Arg
Leptin receptor polymorphism that reduces leptin signaling efficacy can compound the appetite dysregulation from impaired ghrelin suppression. When both ghrelin fails to suppress after meals and leptin fails to signal fullness adequately, the combined effect on caloric intake and weight gain may be substantially larger than either variant alone.

Uterine fibroids (leiomyomas) are benign smooth muscle tumors of the uterus that affect up to 70–80% of women by age 50, causing heavy menstrual bleeding, pelvic pain, and in some cases impaired fertility. Their growth is driven by complex interactions between hormones, genomic instability, and abnormal cell proliferation. rs7907606 is an intergenic variant sitting between two genes with compelling biological relevance to fibroid formation: STN1 (also called OBFC1)¹¹ STN1 (also called OBFC1)
STN1 is a subunit of the CST complex (CTC1-STN1-TEN1) that protects telomere ends and coordinates telomere replication with DNA polymerase alpha-primase and SLK²² SLK
SLK is a serine/threonine kinase involved in cytoskeletal organization, focal adhesion assembly, actin polymerization, and cell migration. Multiple independent GWAS have pinpointed this locus as a reproducible fibroid susceptibility region.

The variant is intergenic — it does not alter a protein directly — and its functional effect appears to be regulatory: it likely modulates the expression of STN1, SLK, or both in uterine tissue. A 2019 trans-ethnic GWAS found that genetically-predicted expression of OBFC1 in esophageal mucosa (a proxy tissue) was significantly associated with fibroid risk³³ A 2019 trans-ethnic GWAS found that genetically-predicted expression of OBFC1 in esophageal mucosa (a proxy tissue) was significantly associated with fibroid risk
P=8.7×10⁻⁸, from Edwards et al. 2019, supporting a gene-expression mechanism rather than a protein-coding one.

Two biological pathways connect these genes to fibroid development. First, the STN1/CST complex maintains telomere integrity — and telomere length itself has a documented causal role in fibroid risk⁴⁴ documented causal role in fibroid risk
Mendelian randomization: genetically longer telomeres increase leiomyoma risk OR=1.73, p=4.9×10⁻¹⁶. Longer telomeres enable smooth muscle cells to undergo more rounds of replication before senescence, which may allow pre-malignant or hormonally dysregulated cells to accumulate the additional mutations required for fibroid initiation. Second, SLK controls cytoskeletal dynamics and focal adhesion assembly — processes that govern how smooth muscle cells attach to the extracellular matrix and migrate within the myometrium. Altered SLK activity could promote the aberrant proliferation and tissue remodeling that characterizes fibroid growth.

The fibroid association at this locus has been replicated across multiple large independent studies. Rafnar et al. (2018) performed a meta-analysis in 16,595 European cases and 523,330 controls⁵⁵ Rafnar et al. (2018) performed a meta-analysis in 16,595 European cases and 523,330 controls
Nature Communications and identified rs7907606 at the OBFC1/STN1 locus as one of 21 variants at 16 genome-wide significant loci, with OR 1.10 (p=3×10⁻⁹). The paper noted that several fibroid loci — including this one — overlapped with loci for other tumors, suggesting shared cancer-related biology. Edwards et al. (2019) extended this work in a trans-ethnic cohort of 21,804 cases⁶⁶ Edwards et al. (2019) extended this work in a trans-ethnic cohort of 21,804 cases
combining eMERGE network data with UK Biobank and confirmed the OBFC1 locus with even stronger evidence (p=2×10⁻¹⁶, OR 1.12, 95% CI 1.09–1.15).

At the clinical level, Ponomareva et al. (2024) genotyped 737 fibroid patients and 451 controls in Russia⁷⁷ Ponomareva et al. (2024) genotyped 737 fibroid patients and 451 controls in Russia
Front Biosci Schol Ed and found an OR of 1.34 (95% CI 1.03–1.74, p=0.028) in women without prior pelvic inflammatory disease — suggesting that infection-related inflammation may mask the genotype effect in women with PID history. Notably, this study identified a significant gene-gene interaction between rs7907606 and rs547025 in SIRT3 (a mitochondrial deacetylase involved in oxidative stress response), which together contributed the most information to fibroid risk entropy of any variant pair tested. This interaction hints at a combined telomere/oxidative stress axis in fibroid susceptibility.

Population frequencies are notably higher in women of African ancestry (G allele ~49%) than in European (16%) or East Asian (18%) populations. This disparity is clinically relevant: African American women have 2–3 times higher fibroid incidence and more severe disease than European American women, and genetic factors at loci like this one may contribute to that disparity.

This is a GWAS susceptibility locus with a moderate effect size (OR 1.10–1.34 per copy), not a deterministic mutation. Having one or two copies of the G allele increases risk but does not cause fibroids. The clinical relevance lies in knowing your risk profile to guide appropriate surveillance — specifically, earlier or more frequent pelvic ultrasound screening for women who are symptomatic or have a family history of fibroids.

Symptom awareness matters: heavy menstrual bleeding, pelvic pressure or pain, frequent urination, or pain during intercourse are common fibroid symptoms that warrant evaluation. Many fibroids are asymptomatic and require no intervention; symptomatic cases have multiple treatment options ranging from medication to minimally invasive procedures.

The interaction with SIRT3 (mitochondrial antioxidant regulation) suggests that oxidative stress management — particularly relevant if you also carry risk variants in oxidative stress pathways — may be biologically meaningful context, though direct intervention evidence for this locus is not yet established.

rs547025 (SIRT3): The strongest gene-gene interaction in fibroid risk identified by Ponomareva et al. (2024) was between rs7907606 and rs547025 in SIRT3, a mitochondrial deacetylase that regulates oxidative phosphorylation and reactive oxygen species production. The combined effect was the largest single pairwise contributor to fibroid risk entropy in that study. The biological model: telomere maintenance stress (STN1/SLK locus) combined with impaired mitochondrial antioxidant activity (SIRT3) may create a permissive cellular environment for fibroid initiation.

rs12696304 (TERC): The TERC locus (telomerase RNA component) directly regulates telomere length. Women who carry risk alleles at both the STN1 locus (rs7907606) and the TERC locus (rs12696304-G) may have additive effects on telomere biology, potentially amplifying the shared causal pathway (longer functional telomere length → greater fibroid susceptibility) identified in the Mendelian randomization data.

The chromosome 2q12 region is one of the most densely connected immune susceptibility loci in the human genome. Packed into a span of less than 300 kilobases are several interleukin-1 receptor family members — IL1RL1 (encoding the IL-33 receptor ST2), IL18R1, and IL18RAP — all of which form a tightly co-regulated signaling hub that links innate immune sensing to Th1 and type-2 inflammatory cascades. rs9807989 sits approximately 1 kilobase upstream of the IL18R1 transcription start site, in a position to influence how much IL-18 receptor is available on immune cell surfaces.

The Mechanism

IL-18¹¹ IL-18
Interleukin-18; an inflammasome-activated cytokine that drives IFN-γ production from T helper 1 cells, NK cells, and NKT cells — a key bridge between innate detection and adaptive Th1 amplification binds a two-chain receptor complex composed of IL-18R1 (the ligand-binding α chain) and IL18RAP (the signal-transducing β chain). When IL-18 binds this complex, it activates NF-κB and MAPK pathways, driving IFN-γ secretion and amplifying macrophage and NK cell activity. The upstream position of rs9807989 places it in the gene's regulatory region, where T/C variation in transcription factor binding sites can affect IL18R1 transcript levels — altering how efficiently immune cells respond when IL-18 is released from activated inflammasomes.

The locus is in partial linkage disequilibrium with the adjacent rs2287037 promoter SNP and the IL18RAP variant rs917997, both of which have been shown to have large cis-effects on receptor expression. Trynka et al. (J Immunology, 2014)²² Trynka et al. (J Immunology, 2014)
IL18RAP region disease polymorphism decreases IL-18RAP/IL-18R1/IL-1R1 surface expression and downstream signaling capacity demonstrated that risk alleles in this region reduce receptor surface availability on monocyte-derived macrophages, impairing MAPK, NF-κB, and calcium-flux responses to both IL-18 and NOD2 stimulation. The haplotype structure of this locus means rs9807989 acts as a tag for cumulative regulatory variation across IL18R1 and its flanking partners.

The Evidence

The most direct evidence for rs9807989 comes from a 2025 case-control study of chronic obstructive pulmonary disease. Ren et al. (Annals of Medicine, 2025)³³ Ren et al. (Annals of Medicine, 2025)
Identification of genetic variants of the IL18R1 gene in association with COPD susceptibility genotyped rs9807989 in 996 subjects (498 COPD cases, 498 healthy controls). The C allele showed strongly protective association against COPD in all tested models — allele (OR 0.42, p<0.001), dominant (OR 0.39, p<0.001), and recessive (OR 0.20, p=0.014). Haplotype analysis placed rs9807989 in Block 1 with the promoter SNP rs2287037; the T(rs9807989)/T(rs2287037) haplotype was associated with increased COPD risk (OR 2.32, p<0.001), confirming additive effects within the LD block.

The broader 2q12 locus is one of the most replicated signals in inflammatory disease genetics. Parkes et al. (Am J Hum Genet, 2008)⁴⁴ Parkes et al. (Am J Hum Genet, 2008)
Genetic analysis of innate immunity in Crohn's disease and ulcerative colitis identifies susceptibility loci harboring IL18RAP demonstrated that variants in the IL1RL1-IL18R1-IL18RAP cluster reach genome-wide significance for both Crohn's disease and ulcerative colitis combined (OR 1.35, p=1.9×10⁻⁸) in 1,851 IBD patients and 1,936 controls. Festen et al. (PLoS Genetics, 2011)⁵⁵ Festen et al. (PLoS Genetics, 2011)
Meta-analysis of GWAS identifies IL18RAP as shared risk locus for Crohn's disease and celiac disease extended these findings, showing shared 2q12 genetic risk across two distinct autoimmune diseases, with the IL18RAP signal reaching p=8.37×10⁻⁸ in combined analysis.

Functionally, the risk alleles at this locus — including the T allele at rs9807989 — are associated with dysregulated IFN-γ responses. Myhr et al. (J Autoimmunity, 2013)⁶⁶ Myhr et al. (J Autoimmunity, 2013)
The autoimmune disease-associated SNP rs917997 of IL18RAP controls IFN-γ production by PBMC showed that cells carrying the susceptibility genotype produce significantly more IFN-γ after IL-12 and IL-18 stimulation (P=0.0296), along with reduced IL-18RAP and IL-18R1 surface protein expression on NK cells — a pattern consistent with compensatory upregulation of remaining receptor complexes or autocrine amplification loops.

Practical Actions

The T risk allele at rs9807989 operates through heightened inflammatory signaling at the IL-18 receptor axis. Relevant actions focus on monitoring biomarkers of IL-18-driven inflammation and managing modifiable factors that activate inflammasomes — the cellular machinery that cleaves IL-18 into its active form.

Interactions

rs9807989 is in linkage disequilibrium with the IL18R1 promoter SNP rs2287037 (same Block 1 haplotype). The adjacent locus tags rs3771166 (IL18R1 intron, GABRIEL asthma GWAS lead) and rs1420101 (IL1RL1 intron, IL-33 pathway sST2 eQTL) represent partially independent signals within the same chromosomal region. Individuals carrying risk alleles at multiple 2q12 nodes accumulate additive susceptibility across the IL-33 and IL-18 receptor arms simultaneously. The IL18RAP variant rs917997 (in LD with the region) is the most studied functional variant at this locus and the primary GWAS signal for IBD and celiac disease association.

Every naïve T cell faces a binary decision when it encounters an antigen: become a Th1 fighter that floods tissue with interferon-gamma (IFN-gamma) to combat intracellular pathogens, or become a Th2 helper that drives IgE and eosinophil-based responses against parasites and allergens. The master switch for the Th1 path is T-bet¹¹ T-bet
encoded by TBX21 (T-box transcription factor 21); the transcription factor that directly activates the IFNG promoter, represses GATA3 and Th2 differentiation, and commits CD4+ T cells to the Th1 effector lineage. rs17699436 sits approximately 5 kb downstream of the TBX21 gene in the intergenic region between TBX21 and OSBPL7 on chromosome 17q21.32. It has been cited alongside TBX21-region variants in association studies of systemic autoimmune disease and is presumed to tag regulatory variation influencing the TBX21-IFNG transcriptional axis.

The Mechanism

rs17699436 maps to chr17:47,751,209 (GRCh38), positioned roughly 5 kilobases 3-prime of the TBX21 transcription end site (chr17:47,746,122). The A>G substitution lies in a region that Ensembl classifies as an intergenic variant with low evolutionary conservation (GERP score −0.48). Its functional significance is not established by direct in vitro assay, but its co-citation with TBX21 promoter and intronic variants in haplotype studies suggests it may be in linkage disequilibrium with regulatory elements that control TBX21 expression. The downstream consequence, if the G allele does tag reduced TBX21 activity, would be blunted T-bet protein output in activated CD4+ T cells — the same mechanism documented for the better-characterized rs4794067 promoter variant.

Fyall et al. (2012)²² Fyall et al. (2012) directly quantified TBX21 promoter variant effects on cytokine output in 210 healthy donors: CC carriers at rs4794067 produced significantly less IFN-gamma (p=0.02) and IL-4 (p=0.001) than TT individuals. If rs17699436 tags this same haplotype block, G-allele carriers would be expected to show a similar, if attenuated, reduction in T-bet-driven IFN-gamma production.

The Evidence

The two publications that index rs17699436 are both systemic autoimmune disease studies. Gourh et al. (2009)³³ Gourh et al. (2009) studied TBX21-region variants in 902 SSc patients and 4,745 controls, finding TBX21 polymorphisms associated with altered Th1/Th2 cytokine balance: SSc patients carrying the high-risk TBX21 haplotype had elevated Th2 cytokines (IL-4, IL-5, IL-13) consistent with reduced T-bet suppression of the Th2 program. rs17699436 was cited as a TBX21-region marker in this context. Leng et al. (2016)⁴⁴ Leng et al. (2016) studied the TBX21/IFNG interaction axis specifically — analyzing rs4794067 (TBX21) against rs2069705 (IFNG) in a 3,732-subject Chinese SLE cohort and found a significant gene-gene interaction: neither variant alone reached significance for SLE susceptibility, but their combination did. This finding establishes the TBX21-IFNG regulatory axis as a unit with compounded autoimmune risk potential.

The broader context for this locus in immune disease comes from studies of the TBX21 haplotype. Munthe-Kaas et al. (2008)⁵⁵ Munthe-Kaas et al. (2008) identified TBX21 intronic variants associated with allergic asthma in Norwegian children with an odds ratio of 8.3 (95% CI 2.5–26.9) for homozygous risk-haplotype carriers, specifically for allergic (IgE-mediated) asthma but not non-allergic asthma. This specificity supports the mechanism: reduced T-bet activity fails to suppress Th2 responses to common allergens, leading to IgE sensitization and airway inflammation.

It is important to be transparent: the direct functional effect of rs17699436 itself has not been independently characterised. The evidence for the G allele's clinical significance is moderate — drawn from haplotype context and co-segregation with better-characterized TBX21 variants — rather than from direct functional assays or independent association studies focused exclusively on rs17699436.

Practical Implications

For G allele carriers, the primary consideration is awareness of the TBX21 regulatory axis: if this variant tags reduced T-bet activity, the practical implications mirror those of other TBX21 hypomorphic variants — a modest shift toward Th2-dominant immune responses with corresponding susceptibility to IgE-mediated allergy, reduced IFN-gamma-driven pathogen defense, and potential vulnerability to autoimmune conditions where the Th1/Th2 balance is mechanistically important. The rarity of GG homozygosity (~0.6% globally) means most carriers are AG heterozygotes, for whom the directional effect is present but attenuated relative to the better-studied CC and TT homozygote patterns at rs4794067.

Interactions

The most established interaction within this locus is between TBX21 and IFNG: T-bet directly binds the IFNG promoter and transactivates IFN-gamma gene expression. Leng et al. (2016) demonstrated that TBX21 and IFNG promoter variants interact epistatically in determining SLE susceptibility — disrupting both ends of the T-bet→IFN-gamma signal chain compounds autoimmune risk beyond either variant alone. Carriers of rs17699436 G who also carry the rs2069705 risk allele in the IFNG promoter may face additive disruption of this axis. The TBX21 haplotype containing rs11650354 and rs16947078 defines the allergic asthma risk in European children; if rs17699436 is in LD with this haplotype block, its allergy-relevant risk operates through the same Th2-permissive mechanism. The rs4794067 promoter variant is the most functionally characterized entry point into this regulatory network and should be checked alongside rs17699436 when assessing T-bet axis risk.

The TNFRSF1A gene encodes TNF receptor 1 (TNFR1)¹¹ TNF receptor 1 (TNFR1)
the primary signaling receptor for tumor necrosis factor-alpha, expressed on nearly all nucleated cells, a central mediator of inflammation and immune defense. When TNF-alpha binds TNFR1, it can trigger apoptosis, pro-inflammatory gene activation, or cell survival depending on context. In the central nervous system, TNF signaling plays a particularly complex role: certain TNF signals are neuroprotective and promote myelin repair, while others drive inflammation. This duality explains one of the most important drug paradoxes in modern medicine: anti-TNF biologics like infliximab, adalimumab, and etanercept — transformative drugs for rheumatoid arthritis and Crohn's disease — consistently worsen multiple sclerosis. A splice-region variant in TNFRSF1A, rs1800693, now explains precisely why.

The Mechanism

rs1800693 sits at the 3′ end of exon 6, 10 nucleotides into the flanking intron, at a position that influences how the pre-mRNA is spliced. The risk allele (C on the plus strand) promotes skipping of exon 6²² The risk allele (C on the plus strand) promotes skipping of exon 6
Exon 6 encodes the transmembrane and cytoplasmic anchor domains of TNFR1; skipping it creates a truncated, secreted protein during mRNA processing. The resulting truncated protein — called TNFRSF1A Δ6, or Δ6-TNFR1 — retains the extracellular TNF-binding domain but lacks the transmembrane and intracellular signaling portions. Without an anchor to the cell membrane, Δ6-TNFR1 is secreted as a soluble, circulating decoy receptor³³ soluble, circulating decoy receptor
Δ6-TNFR1 binds TNF-alpha in the bloodstream and blocks it from engaging membrane-bound TNFR1, with weaker affinity than full-length TNFR1 but still functionally relevant that soaks up free TNF-alpha before it can activate inflammatory signaling.

The Δ6 isoform represents on average 27% of total TNFRSF1A transcript in CC homozygotes, making it a substantial contributor to TNFR1 biology. The key insight from Gregory et al. (Nature, 2012)⁴⁴ Gregory et al. (Nature, 2012)
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis is that Δ6-TNFR1 does exactly what anti-TNF drugs do — it neutralizes TNF-alpha — but at a lower magnitude and with tissue-specific effects the pharmaceutical agents cannot replicate.

The Evidence

De Jager and colleagues⁵⁵ De Jager and colleagues
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nature Genetics 2009 first identified the TNFRSF1A locus in a GWAS meta-analysis of 2,624 MS cases and 7,220 controls, achieving combined p = 1.59×10⁻¹¹. The rs1800693 C allele showed an odds ratio of 1.2 — modest but highly significant due to its common frequency (~41% in Europeans). The locus contains two independent MS-associated variants: rs1800693 (common, OR 1.2) and the nearby coding variant rs4149584/R92Q (rare, 2% allele frequency, OR 1.6).

Replication across 11 European populations⁶⁶ Replication across 11 European populations
Genetic association of variants in CD6, TNFRSF1A and IRF8 to MS: a multicenter case-control study. PLoS ONE 2011 in 7,665 MS cases and 8,051 controls confirmed the association of rs1800693 (p = 4.19×10⁻⁷, OR = 1.12), cementing the locus as a true MS susceptibility signal.

The mechanistic breakthrough came with Gregory et al. Nature 2012⁷⁷ Gregory et al. Nature 2012
rs1800693 C allele generates Δ6-TNFR1, a soluble TNF antagonist explaining why anti-TNF drugs worsen MS: the C allele generates Δ6-TNFR1, which has nanomolar TNF-binding affinity and can neutralize TNF signaling in the CNS — the same mechanism exploited by pharmaceutical TNF inhibitors. Since pharmacological TNF blockade consistently worsens MS (multiple clinical trials were terminated early for this reason), and the rs1800693 C allele generates an endogenous TNF antagonist, this provides a compelling genetic explanation for why anti-TNF therapy is harmful in MS.

Clinical follow-up in 772 MS patients⁸⁸ Clinical follow-up in 772 MS patients
Clinical relevance and functional consequences of the TNFRSF1A MS locus. Neurology 2013 found that rs1800693(C) primarily affects disease onset rather than progression, and that C allele carriers show enhanced monocyte transcriptional responses to TNF-alpha including CXCL10 upregulation. A clinical study of 2,032 MS patients⁹⁹ clinical study of 2,032 MS patients
TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with MS. Neurology 2013 confirmed no severity effect of rs1800693 on disease course.

Practical Implications

The pharmacogenomic significance of this variant is profound. All five approved anti-TNF biologic agents — infliximab (Remicade), adalimumab (Humira), etanercept (Enbrel), golimumab (Simponi), and certolizumab (Cimzia) — carry warnings about new-onset or worsening demyelinating disease, and are absolutely contraindicated in patients with MS or demyelinating disorders. The rs1800693 locus provides the mechanistic explanation: blocking TNF-alpha in the CNS disrupts neuroprotective TNF signaling through TNFR2 and impairs myelin repair mechanisms that are distinct from the peripheral inflammatory effects where anti-TNF therapy is beneficial.

For patients with an autoimmune condition requiring biologic therapy, awareness of this variant helps contextualize the risk. If you develop an inflammatory condition like rheumatoid arthritis or Crohn's disease AND experience neurological symptoms suggestive of demyelination, anti-TNF therapy becomes contraindicated regardless of genotype. The genotype contextualizes the underlying susceptibility mechanism, not just drug risk in isolation.

Interactions

The TNFRSF1A locus harbors two independent MS susceptibility variants: rs1800693 (this entry, common, splice-region) and rs4149584 (R92Q, rare coding variant, OR = 1.6). These are not in strong linkage disequilibrium (r² = 0.041 in HapMap CEU) and confer independent risk. rs4149584/R92Q also causes TRAPS (TNF receptor-associated periodic syndrome)¹⁰¹⁰ TRAPS (TNF receptor-associated periodic syndrome)
an autoinflammatory disorder with recurrent fever, myalgia, abdominal pain, and conjunctivitis at low penetrance — a distinct phenotype from the MS susceptibility conferred by rs1800693.

In the broader TNF pathway, the related promoter variant rs1800629 (TNF-308 G>A in the TNF gene itself) drives elevated TNF-alpha production. These variants interact at a pathway level: high TNF production (rs1800629 A allele) combined with impaired TNF-TNFR1 signaling via the Δ6 decoy isoform (rs1800693 C allele) could perturb the fine-tuned balance of TNF signaling critical in the CNS. No formal compound analysis of these two variants in MS has been published, but the mechanistic logic supports compound monitoring if both risk alleles are present.

The CBS gene encodes cystathionine beta-synthase, a pivotal enzyme that sits at the crossroads of homocysteine metabolism. CBS catalyzes the first step of the transsulfuration pathway, converting homocysteine¹¹ homocysteine
a potentially toxic amino acid when elevated and serine into cystathionine, which is then further metabolized to produce cysteine and glutathione, the body's master antioxidant. This pathway also serves as the only mechanism for removing excess sulfur-containing amino acids from the body. rs1801181, commonly known as A360A or C1080T, is a synonymous variant²² synonymous variant
meaning it doesn't change the amino acid sequence at position 360 of the CBS protein. At first glance, synonymous variants seem inconsequential — after all, the protein sequence remains unchanged. However, this variant has been studied for decades because of its location in a gene central to cardiovascular health and one-carbon metabolism, and because it may subtly influence CBS enzyme expression or activity through effects on mRNA stability or translation efficiency.

The Mechanism

Unlike disease-causing CBS mutations that dramatically reduce enzyme activity and cause homocystinuria³³ homocystinuria
a rare genetic disorder with elevated homocysteine and serious complications, the A360A variant is a common polymorphism. The variant changes the DNA sequence from C to T at codon 360, but due to the degeneracy of the genetic code⁴⁴ degeneracy of the genetic code
multiple DNA codons can encode the same amino acid, both versions code for alanine at this position.

Despite being synonymous, this variant has been investigated for potential functional effects. Synonymous variants can influence gene expression through several mechanisms: altered mRNA secondary structure, changes in translation speed, or effects on mRNA stability. The A (T in genomic coordinates) allele at rs1801181 has been associated with modest differences in CBS enzyme activity in some studies, though the mechanism remains unclear and the effects are far more subtle than those of missense mutations in CBS.

The Evidence

The clinical significance of rs1801181 remains uncertain, earning it a "benign" classification from ClinVar⁵⁵ "benign" classification from ClinVar
the variant is found at high frequency in healthy populations based on its prevalence of approximately 36% in European populations⁶⁶ prevalence of approximately 36% in European populations
too common to cause serious disease. The original characterization of this variant as a common synonymous polymorphism was published in 1994⁷⁷ common synonymous polymorphism was published in 1994
Kraus et al., Human Mutation.

A 2000 case-control study⁸⁸ 2000 case-control study
Kruger et al., Clinical Genetics found that the T allele (A in 23andMe notation) of rs1801181 was associated with decreased risk of coronary artery disease and increased responsiveness to homocysteine lowering by folic acid supplementation. Individuals homozygous for the variant (AA genotype) were significantly underrepresented in CAD patients compared to controls. However, this protective association has not been consistently replicated in subsequent studies.

A 2014 genome-wide meta-analysis⁹⁹ 2014 genome-wide meta-analysis
Williams et al., PLOS Genetics of homocysteine and methionine metabolism identified CBS as one of five major loci affecting one-carbon metabolism, though specific effects of rs1801181 were not the primary focus. The variant has also been weakly associated with modestly elevated risk of non-Hodgkin lymphoma¹⁰¹⁰ modestly elevated risk of non-Hodgkin lymphoma
though the effect size is small and the mechanism unclear, possibly related to interactions with dietary B vitamin and methionine intake.

The evidence for clinical significance remains moderate at best. Most studies suggest that if rs1801181 has any effect on CBS activity or health outcomes, it is subtle and likely modified by dietary factors, other genetic variants in related pathways, and environmental exposures.

Practical Implications

For most people, the A360A variant has minimal direct health implications. Unlike pathogenic CBS mutations that cause dramatically elevated homocysteine requiring medical intervention, this common polymorphism does not typically cause abnormal homocysteine levels on its own. However, it may subtly modulate your body's handling of sulfur-containing amino acids and homocysteine metabolism.

The primary practical consideration is ensuring adequate intake of B vitamins — particularly vitamin B6, which CBS requires as a cofactor, along with folate and vitamin B12, which support the broader methylation and transsulfuration pathways. A diet rich in leafy greens, legumes, whole grains, and protein sources naturally provides these nutrients.

Interactions

CBS variants interact most significantly with other genes in the methylation cycle, particularly MTHFR. The MTHFR enzyme sits upstream of CBS in homocysteine metabolism, converting folate to its active form (5-methyltetrahydrofolate) which is then used to remethylate homocysteine back to methionine. When MTHFR activity is reduced (as with the common C677T or A1298C variants), homocysteine can accumulate. Some have theorized that variations in CBS activity might partially compensate for MTHFR inefficiency by shunting more homocysteine down the transsulfuration pathway, though evidence for this interaction remains preliminary.

The interplay between CBS variants, MTHFR variants, and dietary factors like folate, B6, and methionine intake creates a complex web of influences on homocysteine levels. Individual responses to B vitamin supplementation may vary based on these combined genetic factors, though for common variants like A360A, the effects are typically modest.

The HNF1B gene (hepatocyte nuclear factor 1-beta) encodes a transcription factor that directs the embryonic development of the kidneys, pancreas, liver, urogenital tract, parathyroid, and parts of the brain. Unlike single-organ transcription factors, HNF1β is a master regulator whose influence spans multiple organ systems simultaneously — which is why HNF1B-related disease produces such a diverse and often confusing clinical picture. Pathogenic HNF1B variants cause renal cysts and diabetes syndrome¹¹ renal cysts and diabetes syndrome
Also called MODY5 (maturity-onset diabetes of the young type 5) or HNF1B-related disorder; OMIM 189907, a dominantly-inherited condition that combines early-onset diabetes with kidney abnormalities and a constellation of other organ-system findings.

The rs193922485 variant sits within intron 8 of HNF1B, four nucleotides upstream of the exon 9 splice acceptor site. Its ClinVar annotation NM_000458.4:c.1654-4G>A²² NM_000458.4:c.1654-4G>A
Plus-strand genomic: NC_000017.11:g.37687396C>T; the HNF1B gene is on the minus strand, so the coding-strand G>A corresponds to the plus-strand C>T reflects a position close enough to the splice junction that it was flagged as potentially significant — but computational splice prediction tools and the observation that this nucleotide is not conserved across vertebrate species have led the most recent high-volume clinical laboratories to classify it as likely benign. Three of six ClinVar submitters classify it as likely benign; three as uncertain significance. No published case series documents clinical HNF1B disease in an individual specifically carrying this variant.

The Mechanism

True pathogenic HNF1B variants disrupt haploinsufficiency — one functional copy of HNF1B is insufficient for normal organ development, causing developmental defects in the branching architecture of the kidneys, the differentiation of pancreatic cells (leading to reduced beta-cell mass and early-onset diabetes), magnesium reabsorption in the renal tubule (causing hypomagnesemia), and hepatocyte differentiation. The full syndrome includes renal cysts, early-onset non-immune diabetes, hypomagnesemia, pancreatic dysplasia, and urogenital malformations — often in combination, but rarely all in one individual.

Whether c.1654-4G>A disrupts splicing depends on whether the adenosine substitution at position -4 of the intron creates a novel splice branch point or weakens the polypyrimidine tract. Current in silico tools predict no significant effect on normal splicing at this position, and the non-conserved nucleotide context supports the likely benign interpretation. However, because the clinical consequence of a true splice disruption here would be significant, the variant warrants awareness, particularly in individuals who present with characteristic features of HNF1B-related disease.

The Evidence

HNF1B-related disease is well characterized at the gene level³³ well characterized at the gene level
Verhave JC et al. J Am Soc Nephrol 2016, PMID 26319241. A large cohort study of 61 confirmed MODY5 patients Ge Z et al. 2022⁴⁴ Ge Z et al. 2022
Front Endocrinol, PMID 35846334 found: renal cysts in 72%, hypomagnesemia in 92%, pancreatic dysplasia in 72%, median diabetes onset age of 16 years, and lean body habitus (only 8% overweight). Family history of diabetes was present in 66% — consistent with autosomal dominant inheritance. These data apply to confirmed pathogenic HNF1B variants; the clinical impact of this specific intronic variant is unknown.

The most common type of pathogenic HNF1B change (~40-50% of cases) is a recurrent whole-gene deletion at chromosome 17q12. Point mutations (missense, nonsense, and splice-site) account for the remainder. Intronic variants at the splice acceptor can be pathogenic if they disrupt the AG dinucleotide consensus or the polypyrimidine tract, but variants at position -4 (outside the core splice signal of the last two intronic nucleotides) require functional RNA evidence to confirm pathogenicity.

This specific variant has no published case reports linking it to confirmed HNF1B disease. Its clinical significance therefore remains technically unresolved.

Practical Actions

The primary clinical value of knowing about this variant is awareness: if you carry the T allele and have features consistent with HNF1B-related disease (unexplained renal cysts, early-onset non-immune diabetes, low magnesium, urogenital anomalies), this result supports requesting specialist evaluation and clinical-grade HNF1B testing. If you have none of these features, the variant is most likely benign based on current evidence.

Interactions

The HNF1B gene is the central axis for MODY5 / renal cysts and diabetes syndrome. Other MODY-causing genes (HNF1A for MODY3, HNF4A for MODY1, GCK for MODY2) cause clinically distinct subtypes that require different management — differentiating them requires genetic testing because treatment differs substantially. For blood sugar regulation, TCF7L2 rs7903146 and GCK variants operate in different pathways but converge on insulin secretion and glucose homeostasis.

ABCG2 encodes breast cancer resistance protein (BCRP), an efflux transporter that pumps drugs and metabolites out of cells.

ABCG2 is expressed in the apical membrane of kidney proximal tubule cells and intestinal epithelium , where it mediates excretion of uric acid, rosuvastatin, and other substrates. The Q141K variant (c.421C>A, rs2231142) is one of the most clinically significant pharmacogenetic variants, earning a CPIC Level A recommendation for rosuvastatin dosing due to 144% increased drug exposure in AA carriers .

The Mechanism

The Q141K mutation causes 53% reduced urate transport rates compared to wild-type ABCG2 . The glutamine at position 141 is highly conserved across species¹¹ highly conserved across species
Q141 is located in the nucleotide-binding domain of ABCG2, right next to the corresponding amino acid F508 in CFTR—a residue commonly mutated in cystic fibrosis patients and sits in the nucleotide-binding domain critical for ATP-dependent transport.

The 141K variant causes instability in the nucleotide-binding domain, leading to decreased surface expression, altered protein trafficking, and increased ubiquitin-mediated proteasomal degradation . The result is reduced functional transporter at the cell membrane.

The Evidence

Gout and Hyperuricemia:

In a population study of 14,783 individuals, the rs2231142 T allele showed highly significant associations with elevated urate levels (P = 10^-30 in whites, P = 10^-4 in blacks) and gout (adjusted odds ratio 1.68 per risk allele) .

Among 3,923 Japanese participants, the T allele frequency was 31%, and TT carriers had an OR of 4.37 for gout compared to GG carriers .

A meta-analysis found TT genotype conferred OR 4.10 for gout versus GG, with GT showing intermediate risk , establishing a clear codominant effect.

Functional studies in Xenopus oocytes and membrane vesicles confirmed the Q141K variant results in 53% reduced urate secretory capacity .

Rosuvastatin Pharmacokinetics:

Rosuvastatin exposure (AUC) was 144% greater in c.421AA genotype carriers than wild-type CC carriers .

CPIC recommends a rosuvastatin starting dose of ≤20 mg for individuals with ABCG2 poor function; if higher doses are needed, consider alternative statins or combination therapy .

The high prevalence of the Q141K variant in Asian populations (21% AA genotype in Filipinos, 14% in other Asian groups) versus 0.1-1% in non-Asians has important implications for rosuvastatin dosing .

Methotrexate Clearance:

ABCG2 is one of the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate, working alongside ABCC2 and ABCC3 .

The ABCG2 rs2231142 CA genotype showed statistically significant association with elevated plasma methotrexate levels at 48 hours after high-dose infusion .

Practical Implications

If you're starting a statin: The Q141K variant is the single most important genetic factor for rosuvastatin response. AA carriers have more than double the drug exposure, increasing risk for statin-associated musculoskeletal symptoms²² statin-associated musculoskeletal symptoms
SAMS — muscle pain, weakness, or cramps that prompt many patients to discontinue statins. If you carry two T alleles and your doctor prescribes rosuvastatin, discuss starting at 5-10 mg rather than the standard 10-20 mg dose. Alternative statins metabolized differently (atorvastatin, simvastatin, pravastatin) may be appropriate.

If you have gout or elevated uric acid:

The Q141K variant is associated with elevated serum urate, unaltered fractional excretion of uric acid (FEUA), and significant evidence of reduced extra-renal (intestinal) urate excretion . TT carriers have 2.5-4 times higher gout risk.

Allopurinol is less effective in Q141K carriers, and DPWG recommends using a higher allopurinol dose or considering alternatives like febuxostat .

Population differences matter:

The 141K allele frequency varies from 1% in Africans to 29% in Southeast Asians , making this one of the most ancestry-differentiated pharmacogenes. About 8% of Europeans, 21% of Filipinos, and 7% of East Asians are homozygous TT, explaining population differences in gout prevalence and statin response.

Interactions

ABCG2 and SLC2A9:

Both ABCG2 rs2231142 and SLC2A9 rs3733591 polymorphisms are associated with serum uric acid levels and exhibit gene dose-dependent and additive effects on uric acid elevation . Individuals carrying risk alleles at both loci have substantially higher gout risk than either variant alone, though the combined effect depends on allele counts at each locus. This represents a documented gene-gene interaction in the urate transport pathway that warrants a compound implication covering both variants.

ABCG2 and SLCO1B1: For rosuvastatin specifically, ABCG2 poor function combined with SLCO1B1 decreased function creates compounded exposure risk.

Selection and dosing of rosuvastatin should consider both ABCG2 Q141K status and Asian ancestry , as the interaction between genetic and demographic factors affects pharmacokinetics. A compound implication covering ABCG2 rs2231142 and SLCO1B1 rs4149056 would capture this clinically relevant interaction for rosuvastatin dosing.

PRDM16 (PR/SET Domain 16) is best known as the master transcription factor that drives brown and beige fat cell differentiation — the type of fat that burns calories to produce heat rather than storing them. But a landmark genome-wide association study unexpectedly placed this metabolic gene at the center of migraine biology, revealing a surprising link between thermogenic fat regulation and headache susceptibility.

The Mechanism

The rs2651899 variant sits within the first intron of PRDM16 in a region of moderate linkage disequilibrium¹¹ linkage disequilibrium
LD — the tendency of nearby genetic variants to be inherited together because they sit close on the same chromosome extending roughly 22 kb in each direction. While intronic, this region likely harbors regulatory elements that influence PRDM16 expression levels. PRDM16 protein acts as a transcriptional switch: it activates the thermogenic gene program (including UCP1) in adipocytes and simultaneously represses white fat and smooth muscle gene programs. In the vascular system, PRDM16 maintains beige adipocyte identity in perivascular fat — the fat cushion surrounding blood vessels that modulates vascular tone.

The migraine connection, while not fully resolved, likely involves PRDM16's role in neurovascular regulation. A 2026 study in Science²² 2026 study in Science
Cohen et al. Ablation of Prdm16 and beige fat identity causes vascular remodeling and elevated blood pressure demonstrated that when PRDM16 is lost in adipocytes, beige fat converts to dysfunctional white fat that overproduces the enzyme QSOX1³³ QSOX1
Quiescin sulfhydryl oxidase 1 — an enzyme that promotes collagen cross-linking and tissue fibrosis, triggering vascular fibrosis, increased vascular reactivity, and hypertension. In human cohorts, carriers of PRDM16 mutations showed elevated blood pressure, confirming the mouse findings translate to human biology.

The Evidence

The original GWAS⁴⁴ original GWAS
Chasman et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet, 2011 analyzed 5,122 migraineurs and 18,108 controls from the Women's Genome Health Study, identifying rs2651899 with an odds ratio of 1.11 (95% CI 1.07-1.15, p = 3.8 x 10⁻⁹) — reaching genome-wide significance. This was replicated across three independent cohorts totaling 3,828 additional migraineurs.

A meta-analysis of eight studies⁵⁵ meta-analysis of eight studies
Kowalska et al. Deciphering the role of rs2651899, rs10166942, and rs11172113 polymorphisms in migraine. Medicina, 2022 including 2,320 migraine patients and 2,615 controls found the CC genotype associated with overall migraine risk (OR = 1.32, 95% CI 1.02-1.73) and a stronger effect for migraine with aura (OR = 1.40, 95% CI 1.12-1.74, p = 0.003). A separate meta-analysis⁶⁶ separate meta-analysis
Lee et al. Association of rs2651899 polymorphism in PRDM16 and common migraine subtypes. Headache, 2020 of six studies with 2,853 cases confirmed the recessive model (CC vs CT+TT) showed OR = 1.42 for migraine.

Replication studies in Chinese⁷⁷ Chinese
Zhao et al. PRDM16 rs2651899 variant is a risk factor for Chinese common migraine patients, Indian⁸⁸ Indian, and Pakistani⁹⁹ Pakistani populations have confirmed the association, though with varying effect sizes and migraine subtypes.

Practical Actions

The dual nature of PRDM16 — governing both thermogenic fat and neurovascular function — opens two avenues of action. For migraine susceptibility, mitochondrial-supporting supplements have strong evidence from randomized controlled trials: riboflavin (vitamin B2) at 400 mg/day reduced migraine frequency¹⁰¹⁰ reduced migraine frequency
Schoenen et al. Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology, 1998 by 50% or more in 59% of treated patients (NNT = 2.3), while CoQ10 supplementation¹¹¹¹ CoQ10 supplementation
Sazali et al. Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine. BMJ Open, 2021 reduced attack frequency and duration in meta-analysis. Magnesium (400-600 mg/day as glycinate or threonate) earned a Level B recommendation from the American Headache Society for migraine prevention.

For the thermogenic side, cold exposure protocols (cold showers, outdoor cold exposure) directly stimulate PRDM16-dependent beige fat activation and may help compensate for reduced PRDM16 activity by upregulating thermogenic pathways through sympathetic nervous system signaling.

Interactions

PRDM16 rs2651899 was discovered alongside TRPM8 rs10166942 (a cold-sensing ion channel) in the same migraine GWAS, representing two branches of thermosensory-neurovascular vulnerability. PRDM16 also sits upstream in the same thermogenic cascade as UCP1 (rs1800592) and ADRB3 (rs4994) — variants that independently impair brown/beige fat function. Carrying risk alleles across multiple thermogenic pathway genes could compound both metabolic and neurovascular effects, though direct interaction studies for rs2651899 with these SNPs have not yet been published.

Every meal sends a wave of triglyceride-rich particles into your bloodstream. How quickly those particles are cleared depends partly on a protein called ApoC-III¹¹ ApoC-III
Apolipoprotein C-III — a small protein made in the liver that coats triglyceride-rich lipoproteins and inhibits the enzymes that break them down. The APOC3 gene encodes this protein, and its promoter contains an insulin response element — a molecular switch that normally lets insulin suppress ApoC-III production after eating. The rs2854116 variant disrupts that switch.

The Mechanism

The T-455C variant sits 455 base pairs upstream of the APOC3 coding sequence in a region of the promoter that binds insulin-signaling transcription factors. The common T allele preserves the insulin response element, allowing elevated postprandial insulin to suppress APOC3 transcription and keep ApoC-III levels low while fats are being cleared from the blood. The C allele disrupts this element, so the liver continues producing ApoC-III even when insulin signals "slow down." ApoC-III then inhibits lipoprotein lipase²² lipoprotein lipase
The enzyme that breaks down TG-rich particles on capillary walls throughout the body and hepatic lipase, slowing triglyceride clearance throughout the day.

The companion variant rs2854117 (C-482T) lies in the same promoter region and co-segregates with rs2854116 as part of the APOC3*222 haplotype. Together they account for most of the promoter-level regulation of APOC3 expression.

The Evidence

The landmark Petersen et al. study³³ Petersen et al. study
Petersen KF et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med, 2010 measured the metabolic consequences directly in 95 Asian Indian men. Variant allele (C allele) carriers had 60% higher fasting triglycerides, a 46% reduction in plasma triglyceride clearance rate, and roughly double the post-meal lipid burden compared to TT homozygotes. NAFLD prevalence was 38% among C carriers versus 0% among TT homozygotes (P<0.001). This was replicated in a 163-person non-Asian Indian validation cohort.

A 2003 coronary artery disease study⁴⁴ coronary artery disease study
Olivieri O et al. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res, 2003 of 873 patients found that the -455C allele multiplied coronary artery disease risk in an allele-dose fashion among individuals with metabolic syndrome, with CC carriers showing the highest ApoC-III and triglyceride levels.

A 2003 cohort study⁵⁵ 2003 cohort study
Waterworth DM et al. Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men. Biochim Biophys Acta, 2003 of 502 adults showed that CC homozygotes had approximately 23% lower early insulin secretion and ~10% higher circulating non-esterified fatty acids compared to TT homozygotes, confirming functional disruption of the insulin response element at both the hormonal and metabolic level.

Evidence is not uniformly consistent: a Dallas Heart Study analysis⁶⁶ Dallas Heart Study analysis
Kozlitina J et al. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology, 2011 in 2,497 participants found no significant association between the APOC3 promoter variants and hepatic fat or insulin resistance when analyzed in a multi-ethnic population without metabolic syndrome enrichment, suggesting the effect may be strongest in at-risk metabolic backgrounds.

Practical Actions

The key gene-diet interaction: Olivieri et al. 2005⁷⁷ Olivieri et al. 2005
Olivieri O et al. Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and T-455C APOC3 gene polymorphism in heart disease. Clin Chem, 2005 found that TT and CT carriers lowered ApoC-III progressively as omega-3 (EPA/DHA) intake increased — but CC homozygotes showed the opposite pattern, with elevated omega-3 levels paradoxically associated with higher ApoC-III. This means the standard advice to take fish oil for high triglycerides applies to TT/CT but may not work as expected for CC homozygotes.

A 2023 Japanese study⁸⁸ 2023 Japanese study
Yamamoto R et al. Nutrigenetic Interaction Between APOC3 Polymorphism and Fat Intake in People with NAFLD. Curr Dev Nutr, 2023 of 464 adults found that in TT individuals with NAFLD, fat intake above 25.4% of calories was associated with more severe fatty liver — a dietary threshold specific to TT carriers with established hepatic steatosis.

Postprandial management matters: because ApoC-III impairs TG clearance particularly after meals, strategies that reduce the size and frequency of fat boluses (smaller meals, lower glycemic load) should theoretically benefit C allele carriers by limiting the postprandial TG surge that overwhelmed clearance capacity.

Interactions

The rs2854116 variant co-segregates with rs2854117 (C-482T) as the APOC3*222 haplotype. Carrying both in combination (the full haplotype) may have stronger metabolic effects than either alone. The APOC3 locus also interacts with APOA5 (rs964184) in determining postprandial TG levels — both genes regulate TG-rich lipoprotein clearance through complementary mechanisms. Interaction with ANGPTL3 (rs11207977) is plausible given both proteins modulate lipoprotein lipase activity, though no compound action data are available for this specific combination.